Skip to search formSkip to main contentSkip to account menu

1.75 ML paliperidone palmitate 312 MG/ML Prefilled Syringe [Invega]

Known as: Invega 546 MG per 1.75 ML Prefilled Syringe, Invega Trinza 546 MG in 1.75 ML Prefilled Syringe, 1.75 ML Invega 312 MG/ML Prefilled Syringe 
National Institutes of Health

Related topics

Related topics

9 relations
InvegaPolysorbate 20Prefilled SyringeSodium Hydroxide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Symptomatic and functional outcomes after treatment with paliperidone palmitate 3-month formulation for 52 weeks in patients with clinically stable schizophrenia
Background: Paliperidone palmitate 3-monthly (PP3M) formulation is a long-acting, injectable antipsychotic treatment approved in… 
2016
2016
Invega Trinza: The First Four-Times-a-Year, Long-Acting Injectable Antipsychotic Agent.
Paliperidone palmitate three-month injection (Invega Trinza): the first four-times-a-year, long-acting injectable antipsychotic… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)